MSB 6.07% $1.01 mesoblast limited

banter and General Discussion, page-9303

  1. 808 Posts.
    lightbulb Created with Sketch. 93
    Plus the adult SR-aGvHD trial that will more likely get the FDA green light as the potency assay has been sorted out. Let’s not forget that the market for adult SR-aGvHD is 5 times bigger than the paediatric one.

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.